Dr. Porter

Long only, micro-cap, nano-cap, special situations
Dr. Porter
Long only, micro-cap, nano-cap, special situations
Contributor since: 2012
Thank you and welcome!
Thoughtful contributions to the narrative.
Thank you.
Excellent article.
Thank you and keep up the great work!
Very well done, Mr. Marckx!
Thank you and keep up the fine work.
Thought provoking and eloquently written.
Thank you very much and welcome to SA !
I firmly believe TNX-102 SL will gain FDA approval in both FM and PTSD and quickly become a "blockbuster" drug.
I doubled-down my long position in TNXP.
Thank you very much, SA, for publishing such high-level discourse.
Thank you for this nicely done article.
Current thinking on TASR?
Very interesting. Good job. Thank you!
Ditto....$vix (two above)
Nice article. Thank you!
BRDT is a long-term investment for me.
Outstanding article!
Thank you very much!
Excellent article. Thank you very much.
Keep up the great work !
Mr. Napodano,
Outstanding article! Thank you!
Mr. Napodano,
Thank you for yet another well written article.
I am in full agreement with your assessment of CYNAF.
Thank you for an excellent article!
I whole-heartedly agree with your long thesis.
I have been treating FM, PTSD and other chronic pain syndromes for decades.
I whole-heartedly concur with all of Dr. Flanagan's comments.
Long TNXP.
Thank you for your article.
Very good trial results. Outstanding potential!
Long SNTA.
Outstanding article! Thank you very much.
I fully agree with the long thesis, and for long term. I absolutely expect this product to be spectacularly successful in the marketplace.
Mr. Ibrahim,
Thank you for an informative, helpful article.
I am long ZLCS based on solid, strong data to date as well as truly immense blockbuster potential.
Mr. Napodano,
Thank you for another helpful article.
I remain long DARA, encouraged by this 400% expansion of their sales force and the three complementary new products.
Mr. Spiro,
Thank you for a very well written article.
I believe cancer-specific apoptotic agents hold great promise.
Mr. Napodano,
Thank you for an informative, helpful article.
I am very optimistic on Z160 based on the strong data to date.
Long ZLCS.
Mr. King,
Thank you for an informative, helpful article.
I believe Zerenex will sail through FDA approval and immediately become the standard-of-care in both dialysis and pre-dialysis patients. It is clearly superior to currently available phosphate binders, with the immense added benefit on iron levels. The decreased need for IV iron and expensive ESAs will make it very cost-effective.
Mr. Smith,
Thank you for yet another excellent article.
Mr. Geschek,
Thank you for yet another well-written, informative article.
Mr. Smith,
Thank you for another excellent article.
The trial data on Iluvien is compelling, both safety and efficacy.
I believe the probability of FDA approval is substantially greater than 60%.
Mr. Chase,
Thank you for a very informative article.
I see the same potential as you and am long PLUG.
Mr. Dion,
Thank you for your informative article.
I am long CMRX.
The study published today in the New England Journal of Medicine is very well designed and executed and unequivocally establishes the safety and efficacy of brincidofovir.
I anticipate brincidofovir, already in a Phase III trial, gaining broad usage against all five families of dsDNA viruses which include the herpesviruses and adenoviruses
I believe the venture capital firms, executives and directors which own shares of CMRX recognize the immense potential of brincidofovir and will hold their stakes until far more of that potential is reflected in the share price.